Login to Your Account

Forty Seven lands $75M series A round

By Michael Fitzhugh
Staff Writer

Wednesday, February 24, 2016

Forty Seven Inc., a young company moving a humanized IgG4 kappa anti-CD47 MAb through dual phase I studies, completed the first half of a committed $75 million series A financing led by Lightspeed Venture Partners and Sutter Hill Ventures. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription